Literature DB >> 16301327

The IgD-binding domain of the Moraxella IgD-binding protein MID (MID962-1200) activates human B cells in the presence of T cell cytokines.

Therése Nordström1, Johan Jendholm, Martin Samuelsson, Arne Forsgren, Kristian Riesbeck.   

Abstract

Moraxella catarrhalis immunoglobulin D (IgD)-binding protein (MID) is an outer membrane protein with specific affinity for soluble and cell-bound human IgD. Here, we demonstrate that mutated M. catarrhalis strains devoid of MID show a 75% decreased activation of human B cells as compared with wild-type bacteria. In contrast to MID-expressing Moraxella, the MID-deficient Moraxella mutants did not bind to human CD19+ IgD+ B cells. The smallest MID fragment with preserved IgD-binding capacity comprises 238 amino acids (MID(962-1200)). To prove the specificity of MID(962-1200) for IgD, a Chinese hamster ovary (CHO) cell line expressing membrane-anchored human IgD was manufactured. MID(962-1200) bound strongly to the recombinant IgD on CHO cells. Moreover, MID(962-1200) stimulated peripheral blood lymphocyte (PBL) proliferation 5- and 15-fold at 0.1 and 1.0 microg/ml, respectively. This activation could be blocked completely by antibodies directed against the CD40 ligand (CD154). MID(962-1200) also activated purified B cells in the presence of interleukin (IL)-2 or IL-4. An increased IL-6 production was seen after stimulation with MID(962-1200), as revealed by a human cytokine protein array. MID(962-1200) fused to green fluorescent protein (GFP) bound to human B cells and activated PBL to the same degree as MID(962-1200). Taken together, MID is the only IgD-binding protein in Moraxella. Furthermore, the novel T cell-independent antigen MID(962-1200) may, together with MID(962-1200)-GFP, be considered as promising reagents in the study of IgD-dependent B cell activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301327     DOI: 10.1189/jlb.0205065

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  10 in total

1.  A fusion protein derived from Moraxella catarrhalis and Neisseria meningitidis aimed for immune modulation of human B cells.

Authors:  Oindrilla Mukherjee; Birendra Singh; Burcu Bayrak; Ann-Beth Jonsson; Matthias Mörgelin; Kristian Riesbeck
Journal:  Hum Vaccin Immunother       Date:  2015-06-04       Impact factor: 3.452

2.  Short Leucine-Rich Proteoglycans Modulate Complement Activity and Increase Killing of the Respiratory Pathogen Moraxella catarrhalis.

Authors:  Maisem Laabei; Guanghui Liu; David Ermert; John D Lambris; Kristian Riesbeck; Anna M Blom
Journal:  J Immunol       Date:  2018-09-28       Impact factor: 5.422

3.  Moraxella catarrhalis outer membrane vesicles carry β-lactamase and promote survival of Streptococcus pneumoniae and Haemophilus influenzae by inactivating amoxicillin.

Authors:  Viveka Schaar; Therése Nordström; Matthias Mörgelin; Kristian Riesbeck
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  Comparison of the serological responses to Moraxella catarrhalis immunoglobulin D-binding outer membrane protein and the ubiquitous surface proteins A1 and A2.

Authors:  Thuan Tong Tan; Jens Jørgen Christensen; Morten Hanefeld Dziegiel; Arne Forsgren; Kristian Riesbeck
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

5.  Bacterium-generated nitric oxide hijacks host tumor necrosis factor alpha signaling and modulates the host cell cycle in vitro.

Authors:  Brian Mocca; Wei Wang
Journal:  J Bacteriol       Date:  2012-05-25       Impact factor: 3.490

6.  Moraxella catarrhalis Binds Plasminogen To Evade Host Innate Immunity.

Authors:  Birendra Singh; Tamim Al-Jubair; Chandrashekar Voraganti; Tobias Andersson; Oindrilla Mukherjee; Yu-Ching Su; Peter Zipfel; Kristian Riesbeck
Journal:  Infect Immun       Date:  2015-06-22       Impact factor: 3.441

7.  Identification of domains of the Hag/MID surface protein recognized by systemic and mucosal antibodies in adults with chronic obstructive pulmonary disease following clearance of Moraxella catarrhalis.

Authors:  Eric R LaFontaine; Lauren E Snipes; Brian Bullard; Aimee L Brauer; Sanjay Sethi; Timothy F Murphy
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

8.  AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper.

Authors:  Christoph Bergmann; Aurélie Poli; Ioana Agache; Rodolfo Bianchini; Heather J Bax; Mariana Castells; Silvia Crescioli; David Dombrowicz; Denisa Ferastraoaru; Edda Fiebiger; Hannah J Gould; Karin Hartmann; Elena Izquierdo; Galateja Jordakieva; Debra H Josephs; Marek Jutel; Francesca Levi-Schaffer; Leticia de Las Vecillas; Michael T Lotze; Gabriel Osborn; Mariona Pascal; Frank Redegeld; David Rosenstreich; Franziska Roth-Walter; Carsten Schmidt-Weber; Mohamed Shamji; Esther H Steveling; Michelle C Turner; Eva Untersmayr; Erika Jensen-Jarolim; Sophia N Karagiannis
Journal:  Allergy       Date:  2022-03-14       Impact factor: 14.710

9.  B cell activation by outer membrane vesicles--a novel virulence mechanism.

Authors:  Maria Laura A Perez Vidakovics; Johan Jendholm; Matthias Mörgelin; Anne Månsson; Christer Larsson; Lars-Olaf Cardell; Kristian Riesbeck
Journal:  PLoS Pathog       Date:  2010-01-15       Impact factor: 6.823

10.  B Cell Mobilization, Dissemination, Fine Tuning of Local Antigen Specificity and Isotype Selection in Asthma.

Authors:  Line Ohm-Laursen; Hailong Meng; Kenneth B Hoehn; Nima Nouri; Yue Jiang; Chris Clouser; Timothy G Johnstone; Ron Hause; Balraj S Sandhar; Nadine E G Upton; Elfy B Chevretton; Raj Lakhani; Chris J Corrigan; Steven H Kleinstein; Hannah J Gould
Journal:  Front Immunol       Date:  2021-10-14       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.